Synmosa Biopharma (4114) — Long-term Investment Intensity

Latest as of September 2019: 6.7%

Synmosa Biopharma (4114) has a Long-term Investment Intensity of 6.7% as of September 2019. Long-term investments of NT$581.80 Million represent 6.7% of total assets of NT$8.70 Billion. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check 4114 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

LT Investment Intensity

6.7%
LT Investments / Total Assets

Long-term Investments

NT$581.80 Million
TWD

Total Assets

NT$8.70 Billion
TWD

Country

Taiwan
TWO

Synmosa Biopharma Long-term Investment Intensity (2015–2018)

This chart shows how Synmosa Biopharma's Long-term Investment Intensity has evolved across 4 annual periods from 2015 to 2018. As of September 2019, the intensity stands at 6.7%, reflecting long-term investments of NT$581.80 Million against total assets of NT$8.70 Billion TWD. For the complete balance sheet picture, see Synmosa Biopharma assets under control.

Annual Long-term Investment Intensity for Synmosa Biopharma (2015–2018)

The table below presents the year-by-year Long-term Investment Intensity for Synmosa Biopharma from 2015 to 2018, covering 4 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read debt load of Synmosa Biopharma for a breakdown of total debt and financial obligations.

Year LT Investment Intensity LT Investments (TWD) Total Assets Change (pp)
2018 7.1% NT$536.72 Million NT$7.54 Billion ▼ -3.8 pp
2017 10.9% NT$818.65 Million NT$7.50 Billion ▲ +1.9 pp
2016 9.0% NT$612.26 Million NT$6.79 Billion ▼ -2.1 pp
2015 11.1% NT$511.69 Million NT$4.59 Billion
pp = percentage points